ABSTRACT GABA A receptors composed of ␣ 1 , ␤ 2 , ␥ 1 subunits are expressed in only a few areas of the brain and thus represent interesting drug targets. The pharmacological properties of this receptor subtype, however, are largely unknown. In the present study, we expressed ␣ 1 ␤ 2 ␥ 1 -GABA A receptors in Xenopus laevis oocytes and analyzed their modulation by 21 ligands from 12 structural classes making use of the two-microelectrode voltage-clamp method and a fast perfusion system. Modulation of GABA-induced chloride currents (I GABA ) was studied at GABA concentrations eliciting 5 to 10% of the maximal response. Triazolam, clotiazepam, midazolam, 2-(4-methoxyphenyl)-2, 3,5,6,7,8,9,10-octahydro-cyclohepta-(b) (CGS 9896), diazepam, zolpidem, and bretazenil at 1 M concentrations were able to significantly (Ͼ20%) enhance I GABA in ␣ 1 ␤ 2 ␥ 1 receptors. Methyl-6,7-dimethoxy-4-ethyl-␤-carboline-3-carboxylate, 3-methyl-6-[3-trifluoromethyl-phenyl]-1,2,4-triazolo [4,3-b]pyridazine (Cl 218,872), clobazam, flumazenil,
2-phenyl-4-(3-ethyl-piperidinyl)-quinoline (PK 9084), flurazepam, ethyl-7-methoxy-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a] pyrrolo [2,1-c] [1, 4] benzodiazepine-1-carboxylate (L-655,708), 2-(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-4-methyl-thiazole (Ru 33356), and 6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)phenylmethanone (Ru 32698) (1 M each) had no significant effect, and flunitrazepam and 2-phenyl-4-(4-ethyl-piperidinyl)-quinoline (PK 8165) inhibited I GABA . The most potent compounds triazolam, clotiazepam, midazolam, and CGS 20625 were investigated in more detail on ␣ 1 ␤ 2 ␥ 1 and ␣ 1 ␤ 2 ␥ 2S receptors. The potency and efficiency of these compounds for modulating I GABA was smaller for ␣ 1 ␤ 2 ␥ 1 than for ␣ 1 ␤ 2 ␥ 2S receptors, and their effects on ␣ 1 ␤ 2 ␥ 1 could not be blocked by flumazenil. CGS 20625 displayed the highest efficiency by enhancing at 100 M I GABA (␣ 1 ␤ 2 ␥ 2 ) by 775 Ϯ 17% versus 526 Ϯ 14% I GABA (␣ 1 ␤ 2 ␥ 1 ) and 157 Ϯ 17% I GABA (␣ 1 ␤ 2 ) (p Ͻ 0.05). These data provide new insight into the pharmacological properties of GABA A receptors containing ␥ 1 subunits and may aid in the design of specific ligands for this receptor subtype.
GABA is the principal inhibitory neurotransmitter in the mammalian brain. It mediates fast synaptic inhibition by interaction with the GABA A receptor. GABA A receptors are ligandgated ion channels that are modulated by a large number of clinically relevant drugs such as benzodiazepines (BZs), barbiturates, neurosteroids, and anesthetics (Sieghart, 1995) . They are assembled from individual subunits forming a pentameric structure. Nineteen isoforms of mammalian GABA A receptor subunits have been cloned: ␣ 1-6 , ␤ 1-3 , ␥ 1-3 , ␦, ⑀, p, 1-3 , and (Barnard et al., 1998; Simon et al., 2004) . The major receptor subtype of the GABA A receptor in adults consists of ␣ 1 , ␤ 2 , and ␥ 2 subunits, and the most likely stoichiometry is two ␣ subunits, two ␤ subunits, and one ␥ subunit (Sieghart and Sperk, 2002) . This work was supported by the Austrian Science Fund (Fonds zur Förde-rung der wissenschaftlichen Forschung) grant P12649-MED (to S.H.).
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The subunit composition determines the GABA sensitivity and the pharmacological properties of the GABA A receptor (Sieghart, 1995; Hevers and Luddens, 1998; Boileau et al., 2002) . The subunit composition of the receptor also affects the time course of the GABA response (desensitization and deactivation of the chloride currents) (Bianchi et al., 2001; Boileau et al., 2003; Feng et al., 2004) . Mutation of amino acid residues in ␣ and ␥ 2 subunits modulate the BZ sensitivity of the receptor, suggesting that the BZ binding pocket is located at the interface between ␣ and ␥ 2 (Sigel, 2002; Ernst et al., 2003) . There is clear evidence that substitution of the ␥ 2 subunit by either ␥ 1 or ␥ 3 significantly alters the sensitivity for BZ (Hevers and Luddens, 1998) .
In contrast to the ␥ 2 subunit, which is ubiquitously expressed in the central nervous system, the ␥ 1 subunit is expressed in only a few areas of the brain such as the amygdala (central and medial nuclei), the pallidum, the septum, the substantia nigra, and the thalamus (centrolateral and medial nuclei) (Pirker et al., 2000; Korpi et al., 2002) . Compounds selectively interacting with receptors containing ␥ 1 subunits thus might have a substantial clinical potential.
Compared with receptors containing ␥ 2 subunits, little is known about the pharmacological profile of GABA A channels composed of ␣ 1 , ␤ 2 , and ␥ 1 subunits. Ymer et al. (1990) observed a loss in affinity for the benzodiazepine antagonist Ro 15-1788 and the inverse agonist methyl-6,7-dimethoxy-4-ethyl-␤-carboline-3-carboxylate (DMCM) when the ␥ 1 was substituted for ␥ 2 in ␣ 1 ␤ 1 ␥ 2 receptors. Negative modulatory effects of Ro 15-4513, ␤-CCM, and DMCM for GABA A receptors composed of ␣ 1/2/3 ␤ 1 ␥ 2 subunits are changed to positive modulatory effects in ␣ 1/2/3 ␤ 1 ␥ 1 receptors (Puia et al., 1991; Wafford et al., 1993) . Benke et al. (1996) observed a low affinity for clonazepam, zolpidem, and flunitrazepam and apparent insensitivity for flumazenil and Ro 15-4513 for ␥ 1 -containing receptors. Wafford et al. (1993) demonstrated a reduced enhancement of chloride currents through ␣ 3 ␤ 2 ␥ 3 by diazepam, clonazepam, and bretazenil compared with ␣ 3 ␤ 2 ␥ 2 and a negative modulatory effect of zolpidem for ␣ 2 ␤ 1 ␥ 1 and alpidem for ␣ 3 ␤ 1 ␥ 1 receptors.
Overall, in 4 different studies, a total of 14 compounds from 5 different compound classes have been investigated so far for their ability to modulate GABA A receptors containing ␥ 1 subunits. Unfortunately, most of these studies were carried out under different experimental conditions and with receptors containing different ␣ and ␤ subunits combined with ␥ 1 . Thus, the relative efficacies of these compounds for ␣␤␥ 1 are not comparable (Hevers and Luddens, 1998) .
In the present study, we analyzed the modulation of ␣ 1 ␤ 2 ␥ 1 receptors expressed in Xenopus laevis oocytes by 21 compounds comprising distinct chemical structures. Triazolam, clotiazepam, midazolam, and CGS 20625 exhibited a significant potency and efficiency, whereas the other compounds were either inactive or displayed only a low potency on ␥ 1 -containing receptors.
Materials and Methods
Chemicals. Compounds were obtained from the following sources: Ro 15-1788, and bretazenil [t-butyl(s)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a] Ogris et al. (2004) .
Expression and Functional Characterization of GABA A Receptors. X. laevis oocytes were prepared and injected as described previously (Grabner et al., 1996) . Female X. laevis (Nasco, Fort Atkinson, WI) were anesthetized by exposing them for 15 min to a 0.2% MS-222 (methane sulfonate salt of 3-aminobenzoic acid ethyl ester; Novartis) solution before surgically removing parts of the ovaries. Follicle membranes from isolated oocytes were enzymatically digested with 2 mg/ml collagenase (type 1A, Sigma). One day after isolation, the oocytes were injected with approximately 10 to 50 nl of a solution of diethyl pyrocarbonate water containing the different cRNAs at a concentration of approximately 300 to 3000 pg/nl/ subunit. The amount of cRNA was determined by means of a NanoDrop ND-1000 (Kisker-Biotech, Steinfurt, Germany). To ensure expression of the ␥ subunit in the case of ␣ 1 ␤ 2 ␥ 1 and ␣ 1 ␤ 2 ␥ 2S receptors, cRNAs were mixed in a ratio of 1:1:10, and for receptors comprising only ␣ 1 and ␤ 2 subunits, they were mixed in a ratio of 1:1 (Boileau et al., 2002) .
Oocytes were stored at 18°C in ND96 solution (Methfessel et al., 1986) . Electrophysiological experiments were performed by the twoelectrode voltage-clamp method making use of a TURBO TEC 01C amplifier (NPI Electronic GmbH, Tamm, Germany) at a holding potential of Ϫ70 mV. The bath solution contained 90 mM NaCl, 1 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , and 5 mM HEPES, pH 7.4. Perfusion System. GABA was applied by means of a modified version of a fast perfusion system according to Hering (1998) . A schematic drawing of the perfusion chamber and drug application device is shown in Fig. 1A . As described previously, the voltageclamp experiments on X. laevis oocytes were performed in a small (Ϸ15 l) bath that was covered by a glass plate. Two angular inlet channels in the glass cover (diameter, Ͻ1 mm) enabled access of the two microelectrodes to the oocyte. A funnel for drug application surrounded both access channels for the microelectrodes compared with a funnel surrounding a single access channel in Hering (1998) . This modification increased the stability of oocyte perfusion.
Drug or control solutions were applied to the funnel by means of a Miniprep 60 (Tecan, Durham, NC) that was controlled by a DigiData 1322A (Clampex version 9.2; Molecular Devices, Sunnyvale, CA), permitting automation of the experiments [see also Supplemental Videos S1 and S2 (files methods_1.avi and methods_2.avi) for animation of the solution exchange].
To estimate the rate of solution exchange independent of the ligand-receptor interaction, we expressed K v 1.1 channels in X. laevis oocytes and analyzed the time course of current decay during a rapid increase of the extracellular potassium concentration from 1 to 10 mM (sodium was reduced to 80 mM, respectively). Figure 1B illustrates a typical K v 1.1 current during a voltage-clamp step from Ϫ80 to ϩ20 mV. The current decrease upon fast perfusion with 10 mM potassium at a speed of 1 ml/s is shown on the right in Fig. 1B . A GABA A Receptors Containing ␥1 Subunits 641 at ASPET Journals on January 6, 2018 molpharm.aspetjournals.org mean current decline time t 10-90% of 140.8 Ϯ 17.5 ms (n ϭ 7) was estimated.
To elicit GABA-induced chloride currents (I GABA ), the chamber was perfused with 120 l of GABA-containing solution at the same volume rate (1 ml/s). The rise time of I GABA ranged usually between 100 and 250 ms (Fig. 1C) , which is comparable with the rate of solution exchange estimated in Fig. 1B .
After the initial fast perfusion step for rapid agonist application, the chamber was continuously perfused at a rate of 1 l/s for a total of 18 s. Before rapid washout of agonist and/or drug, the funnel was emptied by a suction pulse applied to the two funnel outlets (Fig. 1A) .
The time between this suction pulse and the application of new solution to the funnel was Ͻ1 s to avoid evaporation of the bath surrounding the oocyte.
Duration of washout periods was extended from 3 to 30 min, with increasing concentrations of applied GABA to account for slow recovery from increasing levels of apparent desensitization. Oocytes with maximal current amplitudes Ͼ3 A were discarded to minimize voltage-clamp errors.
Analyzing Concentration-Response Curves. Enhancement of chloride currents by modulators of the GABA A receptor was measured at a GABA concentration eliciting between 5 and 10% of the maximal current amplitude (EC 5-10 ). The EC 5-10 (usually ranging between 3 and 8 M) was determined at the beginning of each experiment.
Enhancement of the chloride current (I GABA ) was defined as (I (GABA ϩ Comp) /I GABA ) Ϫ 1, where I (GABA ϩ Comp) is the current response in the presence of a given compound, and I GABA is the control GABA current. To measure the sensitivity of the GABA A receptor for a A, cross-section view of the oocyte perfusion chamber. Two microelectrodes (M1 and M2) are inserted into the angular access inlets in a glass plate (the inlets serve simultaneously as perfusion holes) covering the small (Ϸ15 l) oocyte chamber. Drug was applied by a Tecan Miniprep 60 application tube (AT) to a quartz funnel surrounding the microelectrode access holes (MAH). Residual solution was removed from the funnel before drug application via the funnel outlets (see Hering, 1998 and the two Supplemental Video files S1 and S2). B, estimation of the rate of solution exchange on an oocyte expressing Kv 1.1 the extracellular potassium concentration was rapidly increased from 1 to 10 mM during a potassium outward current (voltage step from Ϫ80 to ϩ20 mV). The time of current decrease (right) from 10 to 90% (t 10 -90% ) was taken as a measure of the volume rate of oocyte perfusion. C, typical time courses of I GABA (␣ 1 ␤ 2 ␥ 2S receptors) activated by different GABA concentrations. Upon application of 300 M GABA, I GABA increased from 10 to 90% within 100 ms. At 100, 30, and 10 M GABA t 10 -90% was 140, 180, and 230 ms, respectively. at ASPET Journals on January 6, 2018 molpharm.aspetjournals.org given compound, it was applied for an equilibration period of 1 min before concomitant application of GABA ) and increasing concentrations of the compound. None of the compounds investigated was able to induce chloride flux in the absence of GABA. Concentration-response curves were generated, and the data were fitted by nonlinear regression analysis using ORIGIN software (OriginLab Corp, Northampton, MA). Data were fitted to the equation 1/(1 ϩ (EC 50 /[Comp]) nH ), where EC 50 is the concentration of the compound that increases the amplitude of the GABA-evoked current by 50%, and n H is the Hill coefficient. Data are given as mean Ϯ S.E. from at least four oocytes and Ն2 oocyte batches. Statistical significance was calculated using unpaired Student's t test with a confidence interval of p Ͻ 0.05. In a first step, GABA A receptors were activated by GABA concentrations corresponding to EC 5-10 , and drug effects were screened at a single concentration of 1 M. As illustrated in Fig. 2 (Ⅺ) , only the benzodiazepines triazolam, midazolam, and diazepam, the thienodiazepine clotiazepam, the pyrazolopyridine CGS 20625, and the pyrazoloquinoline CGS 9896 induced an enhancement of Ͼ20% at this concentration. The other compounds induced either a very small but statistically significant enhancement (zolpidem and bretazenil), no statistically significant effect (DMCM, Cl 218,872, clobazam, flumazenil, Ru 33203, PK 9084, flurazepam, L-655,708, Ru 31719, Ru 33356, and Ru 32698), or even an inhibition of GABA-induced chloride currents (flunitrazepam and PK 8165), and details are given in Table 1 .
Results

Modulation
To establish compounds displaying low potency but high efficiency, all compounds were subsequently tested at higher concentrations (10 and 100 M) (Fig. 2A) . Modulation of GABA receptors at low GABA concentrations (EC 5-10 close to "tonic concentrations") can substantially differ from modulation at high concentrations (i.e., millimolar "synaptic concentrations"). We have, therefore, analyzed the effects of all 21 compounds at 1 mM GABA (Fig. 3A) . None of the compounds, however, substantially enhanced or inhibited I GABA . Representative chloride currents induced by 1 mM in the absence or presence of 1 M triazolam or CGS 20625 are shown in Fig. 3B .
Contribution of ␣ 1 ␤ 2 Receptors. Previous studies have clearly shown that the extent of the incorporation of ␥ subunits into heterologously expressed GABA A receptors may vary between oocyte batches and decrease with time ( Boileau   Fig. 3 . A, modulation of chloride currents through GABA A receptors composed of ␣ 1 ␤ 2 ␥ 1 subunits at 1 mM GABA by 1 M concentration of the indicated compounds. ‫,ء‬ statistically significant differences from 0 (p Ͻ 0.05, t test by ANOVA). B, typical enhancement of I GABA through ␣ 1 ␤ 2 ␥ 1 channels induced by 1 mM GABA in the absence (control, left traces) and presence of 1 M triazolam and 1 M CGS 20625. A comparison with the concentration-response data obtained on GABA A channels containing ␥ 2S subunits reveals a 3-fold higher efficiency of triazolam, a 1.5-fold higher efficiency of clotiazepam, and a 3.7-fold higher efficiency of midazolam on ␣ 1 ␤ 2 ␥ 2S receptors. The ratio of the EC 50 values for triazolam, clotiazepam, and midazolam (EC 50/␥1 /EC 50/␥2S ) reflect 4-, 9-, and 8-fold lower potencies of these compounds for ␣ 1 ␤ 2 ␥ 1 receptors, respectively ( Table 2 ). The apparent EC 50 values, maximum enhancement, and the corresponding ratios for the benzodiazepines tested are given in Table 2 . Modulation of I GABA by Triazolam, Clotiazepam, and Midazolam at Different GABA Concentrations. To gain insight into the mechanism of I GABA enhancement, we studied the GABA dose-effect curves in the absence and presence of the modulators. The results are shown in Fig. 5 , A to C. In control, the mean EC 50 value for GABA was 39 Ϯ 3 M in ␣ 1 ␤ 2 ␥ 1 receptors and 50 Ϯ 3 M in ␣ 1 ␤ 2 ␥ 2S receptors. The three benzodiazepine receptor ligands shifted the dose-effect curves to the left without affecting the maximal response (Fig. 3A) . It is noteworthy that the drug-induced shift was more pronounced for ␣ 1 ␤ 2 ␥ 2S than for ␣ 1 ␤ 2 ␥ 1 receptors, reflecting the higher efficiency of these ligands on ␣ 1 ␤ 2 ␥ 2S .
Effect of the Pyrazolopyridine CGS 20625 on ␣ 1 ␤ 2 , ␣ 1 ␤ 2 ␥ 1 and ␣ 1 ␤ 2 ␥ 2S Receptors. CGS 20625 elicited maximum enhancement of chloride currents through ␣ 1 ␤ 2 ␥ 1 receptors of approximately 645%, with a half-maximal enhancement occurring at approximately 20 M (Fig. 6B) . CGS 20625 thus represents a low potency but highly efficient positive modulator of ␣ 1 ␤ 2 ␥ 1 receptors. This compound enhanced the GABA response of ␣ 1 ␤ 2 ␥ 2S receptors with comparable efficiency (I max/␥2 /I max/␥1 Ϸ 1.12) and was less efficient on ␣ 1 ␤ 2 receptors (Fig. 6B) . At higher CGS 20625 concentrations (Ն300 M), we observed weaker enhancement of the GABA-induced chloride flux than at 100 M for all subunit compositions (Fig. 6B) . Table 2 ). Data points represent means Ϯ S.E. from at least four oocytes from Ն2 batches. 
The maximum enhancement (percentage of control) and EC 50 values were calculated by fitting the data points to a standard concentration-response curve. Rightmost column represents ratios between EC 50 values of ␣ 1 ␤ 2 ␥ 1 and ␣ 1 ␤ 2 ␥ 2S receptors. Effect of Flumazenil on ␣ 1 ␤ 2 ␥ 1 Receptors. Flumazenil is a ligand of the BZ binding site of ␣ 1 ␤ 2 ␥ 2 GABA A receptors and competitively inhibits the enhancement of GABA-induced chloride currents by benzodiazepine agonists (Wafford et al., 1993) . It was therefore interesting whether this compound would also inhibit the effects of triazolam and clotiazepam on ␣ 1 ␤ 2 ␥ 1 receptors. Figure 7 , A and B (left), illustrates the inhibition by flumazenil of triazolam-or clotiazepam-induced I GABA enhancement in ␣ 1 ␤ 2 ␥ 2S receptors. As shown on the right, the effects of triazolam or clotiazepam on ␣ 1 ␤ 2 ␥ 1 receptors were not inhibited by 1 M flumazenil. Moreover, we were unable to study possible antagonistic effects at higher concentrations, because flumazenil induced significant enhancement of I GABA in oocytes expressing ␣ 1 ␤ 2 ␥ 1 subunits at 10 (22 Ϯ 2%, n ϭ 4) and 100 M (64 Ϯ 8%, n ϭ 4; Fig. 7C ). 
Discussion
In the present study, we made use of a fast and automated perfusion technique (Fig. 1) to test a selection of 21 modulators on GABA A receptors composed of ␣ 1 ␤ 2 ␥ 1 subunits. Solution exchange occurred between 100 and 250 ms (see Materials and Methods and Fig. 1C) , which reduced the effects of desensitization on peak current detection compared with conventional bath perfusion.
I the GABA-induced chloride flux. Application of higher concentrations (10 and 100 M) revealed a moderate enhancement at high concentrations (low-potency modulation) by bretazenil, DMCM, flumazenil, Ru 33203, Ru 32698, and flunitrazepam. All compounds were tested in the absence of GABA (data not shown). None of them induced measurable currents, even at high concentrations (up to 100 M). Thus, the 1,4-benzodiazepines triazolam and midazolam, the 1,4-thienodiazepine clotiazepam, and the pyrazolopyridine CGS 20625 seemed to be the most promising candidates for further detailed analysis.
Contribution of the ␥ 1 Subunit to the Enhancement of I GABA . On injection of X. laevis oocytes with ␣, ␤, and ␥ subunits, not only are receptors containing all three subunits formed but possibly also receptors composed of ␣ and ␤ subunits only (Boileau et al., 2002) . To investigate whether the observed drug effects were caused by effects on ␣ 1 ␤ 2 ␥ 1 receptors or could also be explained by effects on ␣ 1 ␤ 2 receptors, the effects of drugs on the latter receptors were also investigated. A comparison of drug effects on ␣ 1 ␤ 2 ␥ 1 and ␣ 1 ␤ 2 receptors revealed that the ␥ 1 subunit was essential for enhancement of I GABA by triazolam, clotiazepam, and midazolam (Table 1 and Fig. 2 ), because these compounds at 1 M concentration induced a significant inhibition by Ϫ21 Ϯ 4% (n ϭ 12, p Ͻ 0.05), (Ϫ14 Ϯ 2%, n ϭ 6), and (Ϫ20 Ϯ 5%, n ϭ 6), respectively, of I GABA through ␣ 1 ␤ 2 subunit receptors. In addition, the effects of several other drugs were clearly different in ␣ 1 ␤ 2 ␥ 1 and ␣ 1 ␤ 2 receptors. Thus, CGS 20625, CGS 9896, diazepam, zolpidem, and bretazenil exhibited an enhancement of I GABA that was higher in ␣ 1 ␤ 2 ␥ 1 than in ␣ 1 ␤ 2 receptors, supporting the importance of the ␥ 1 subunit for the effects observed. Finally, Cl 218,872 and flurazepam exhibited effects in opposite direction in ␣ 1 ␤ 2 ␥ 1 and ␣ 1 ␤ 2 receptors, again supporting the conclusion that the drug effects observed on injection of oocytes with ␣ 1 , ␤ 2 , and ␥ 1 subunits were predominantly caused by ␣ 1 ␤ 2 ␥ 1 receptors (Table 1) .
Our finding that triazolam, clotiazepam, and midazolam significantly inhibit I GABA through ␣ 1 ␤ 2 receptors suggests that we might have underestimated the enhancement of I GABA in ␣ 1 ␤ 2 ␥ 1 receptors by these drugs because of simultaneously occurring inhibition of ␣ 1 ␤ 2 subunit receptors. The differential effects of various BZ binding site ligands on receptors composed of ␣ 1 ␤ 2 subunits are highly interesting by themselves and significantly extend previous evidence for the existence of a low-affinity benzodiazepine binding site at ␣␤ receptors (Wafford et al., 1993; Thomet et al., 1999; Walters et al., 2000) .
To determine the potency and efficiency (maximum ability to enhance the GABA EC 5-10 response of the three most potent BZ; Table 2 ), we studied their concentration effect for receptors composed of ␣ 1 ␤ 2 ␥ 1 subunits (Fig. 3) . The 1,4-benzodiazepine triazolam displayed the highest potency (EC 50 Ϸ 90 nM), followed by midazolam (EC 50 Ϸ 1.2 M) and the 1,4-thienodiazepine clotiazepam (EC 50 Ϸ 1.7 M, Table 2 ). A comparison of the concentration-effect curves for these benzodiazepine-type ligands with receptors composed of ␣ 1 ␤ 2 ␥ 2S receptors revealed a significantly lower efficiency and potency for ␥ 1 -containing receptors (Fig. 3 and Table 2 ). 
